Entering text into the input field will update the search result below

Lexaria gets independent review board nod for its human oral nicotine study

Nov. 01, 2022 9:40 AM ETLexaria Bioscience Corp. (LEXX) StockBy: Anuron Mitra, SA News Editor1 Comment

snus nicotine pouch product on concrete background. outer space. chewing nicotine bags. danger unhealthy addiction

Andrii Atanov/iStock via Getty Images

  • Lexaria Bioscience (NASDAQ:LEXX) on Tuesday said an independent review board had approved the company's human clinical nicotine study.
  • The study, called NIC-H22-1, will compare the performance of LEXX's DehydraTECH-nicotine pouch to existing brands On! by Altria (

Recommended For You

About LEXX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LEXX--
Lexaria Bioscience Corp.